Delving into the Latest Updates on Motixafortide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Motixafortide Acetate, 莫替福肽, 4F-BENZOYL-TN14003

+ [7]

Target

CXCR4

Action

antagonists

Mechanism

CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Multiple MyelomaPancreatic Ductal CarcinomaPancreatic Cancer+ [2]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Promyelocytic Leukemia+ [12]

Originator Organization

Biokine Therapeutics Ltd.

Active Organization

BioLineRx Ltd.

Biogen, Inc.

Guangzhou Gloria Biosciences Co., Ltd.

+ [2]

Inactive Organization

The University of Texas MD Anderson Cancer Center

Washington University School of Medicine

Biokine Therapeutics Ltd.

License Organization

Guangzhou Gloria Biosciences Co., Ltd.

Genfleet Therapeutics (Shanghai), Inc.

Gamida Cell Ltd.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (08 Sep 2023),

Multiple Myeloma

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaC97H144FN33O19S2

InChIKeyJJVZSYKFCOBILL-KZGZZEQFSA-N

CAS Registry664334-36-5

Sequence Code 528941150

Source: *****

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.

Start Date01 Dec 2025

Sponsor / Collaborator

Guangzhou Gloria Biosciences Co., Ltd.

NCT07101445

/ RecruitingPhase 4IIT

Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)

This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transplantation (ASCT) have better outcomes. However, not all MM patients are able to have a successful stem cell mobilization and collection which is needed to proceed to ASCT. The addition of motixafortide prior to stem cell mobilization has allowed more MM patients to collect the needed number of stem cells to proceed to ASCT. However, motixafortide does produce systemic and injection site reactions in many patients. The optimal medication regimen to prevent reactions remains unknown. A premedication regimen with dexamethasone prior to motixafortide decreases the incidence of reactions in many patients and is considered the standard of care regimen for the prevention of systemic and injection site reactions to motixafortide in patients with MM undergoing stem cell mobilization. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen side effects/allergic reactions. However, dexamethasone is associated with other side effects like headache, difficulty sleeping, high blood glucose, high blood pressure, mood changes, fluid retention, and infection, among others. A premedication regimen with methylprednisolone prior to motixafortide may work better to decrease the incidence of reactions to motixafortide in patients with MM undergoing stem cell mobilization. Methylprednisolone is in a class of medications called corticosteroids. It works to decrease side effects/allergic reactions by changing the way the immune system works. Giving methylprednisolone may be safe, tolerable and/or more effective than dexamethasone as part of a premedication regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization.

Start Date24 Sep 2025

Sponsor / Collaborator

Emory University

[+2]

NCT06506461

/ RecruitingPhase 1IIT

St. Jude Autologous Genome Edited Stem Cells For Sickle Cell Disease-1

This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD.
Primary Objective
* To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.
Secondary Objective
* To assess the efficacy autologous infusion of CRISPR/Cas9 genome-edited CD34+ HSPCs into patients with severe SCD.

Start Date21 Mar 2025

Sponsor / Collaborator

St. Jude Children's Research Hospital, Inc.

[+1]

100 Clinical Results associated with Motixafortide

Login to view more data

100 Translational Medicine associated with Motixafortide

Login to view more data

100 Patents (Medical) associated with Motixafortide

Login to view more data

81

Literatures (Medical) associated with Motixafortide

01 Jul 2025·BIOMEDICAL CHROMATOGRAPHY

Development and Validation of the LC–MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma

Article

Author: Shaik, Afzal B. ; Mary K, Lurdhu ; Podila, Naresh ; Chimakurthy, Jithendra

ABSTRACT:

Introduction:

Motixafortide, a CXCR4 antagonist, and filgrastim, a granulocyte colony‐stimulating factor, have shown significant potential in enhancing hematopoietic stem cell mobilization and improving cancer treatment outcomes when used in combination. However, critical challenges persist due to the absence of analytical methods and the necessity for reliable quantification of both drugs in biological matrices. This research aims to address these gaps by developing and validating a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of motixafortide and filgrastim in rat plasma.

Experiment:

An isocratic mobile phase with acetonitrile and buffer was employed for separation, following protein precipitation with acetonitrile, using a C18 Waters X‐Terra RP‐18 column (150x4.6 mm,3.5 μm). Liquid chromatography–tandem mass spectrometry with an internal standard employs multiple reaction monitoring in electrospray ionization (positive ion mode) to monitor the transitions. The method was validated according to USFDA guidelines, assessing parameters such as selectivity, matrix effect, linearity, precision, accuracy, lower limit of quantification, and stability.

Results:

This method was successfully applied in pharmacokinetic studies, ensuring reliable and accurate quantification of co‐administered motixafortide and filgrastim. These findings significantly contribute to optimizing therapeutic protocols and enhancing treatment outcomes for cancer patients.

03 Apr 2025·EXPERT OPINION ON THERAPEUTIC PATENTS

Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024

Review

Author: Wilson, Lawrence J. ; Liotta, Dennis C. ; Tahirovic, Yesim A. ; Geng, Jiafeng ; Sahin, Zafer

INTRODUCTION:

The chemokine receptor CXCR4 has been under intense study due to the central role it plays in immune system regulation and the pathology of human disease. Although the first CXCR4 drug plerixafor emerged over a decade ago (2007), recently the first peptide (motixafortide, 2023) and the first oral small molecule (mavorixafor, 2024) CXCR4 antagonists became FDA approved.

AREAS COVERED:

This article describes patent documents published during the period of 2019 through 2024 for both small molecule and peptides. This IP includes few new chemotypes, with most being extensions of existing structural classes. There is also less significant IP covering peptide-based therapeutics than those covering small molecules. Notably, multiple therapeutic uses have also emerged. Patents were searched from SciFinder (CAS) and Google Patents with the term CXCR4 antagonists. Patents were selected according to whether they fit into the classification of small molecules or peptides.

EXPERT OPINION:

In the last 5 years there has been significant advancement in CXCR4 antagonists as gauged by the FDA approval of two drugs. The search for second and third generation compounds will be the focus of future efforts with new uses and better properties which likely could come from some of the IP described herein.

01 Nov 2024·LEUKEMIA

CXCR4 as a therapeutic target in acute myeloid leukemia

Review

Author: Chlubek, Dariusz ; Bosiacki, Mateusz ; Barczak, Katarzyna ; Kupnicka, Patrycja ; Korbecki, Jan ; Baranowska-Bosiacka, Irena

Extensive research on the CXCL12-CXCR4 axis in acute myeloid leukemia (AML) has resulted in the incorporation of novel anti-leukemia drugs targeting this axis into therapeutic strategies. However, despite this progress, a comprehensive and up-to-date review addressing the role of the CXCL12-CXCR4 axis in AML's oncogenic processes is lacking. In this review, we examine its molecular aspects influencing cancer progression, such as its impact on autonomous proliferation, apoptotic regulation, chemoresistance mechanisms, and interactions with non-leukemic cells such as MSCs and T_reg cells. Additionally, we explore clinical implications, including prognosis, correlation with WBC count, blast count in the bone marrow and peripheral blood, as well as its association with FLT3-ITD, NPM1 mutations, and FAB classification. Finally, this paper extensively discusses drugs that specifically target the CXCL12-CXCR4 axis, including plerixafor/AMD3100, ulocuplumab, peptide E5, and motixafortide, shedding light on their potential therapeutic value in the treatment of AML.

102

News (Medical) associated with Motixafortide

16 Dec 2025

·www.businesswire.com

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

BOSTON--(BUSINESS WIRE)--Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe aplastic anemia,” said Dr Joe Wiley, Chairman and Chief Executive Officer of Ayrmid Ltd. “This important strategic partnership enhances our dual sourcing approach and secures patient supply in the longer term.” “The expansion of Omisirge®’s commercial manufacturing at RoslinCT demonstrates the strength of our partnership and the capability of our facilities to support innovative therapies at scale,” said Peter Coleman, Chief Executive Officer of RoslinCT. “Alongside Omisirge®, we continue to progress multiple cell therapy projects, reflecting our commitment to enabling transformative treatments for patients worldwide.” About Omisirge® Omisirge® is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from the youngest donor source, designed for ease of infusion. The product is FDA-approved and commercialized for patients with hematologic malignancies. With the new indication, Omisirge® now provides treatment options for a broader patient population, enhancing its potential to improve outcomes. About RoslinCT RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2005 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1996, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge (please see the current full Prescribing Information, including boxed warning, here) and APHEXDA® (please see the current full Prescribing Information here). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram.

Cell TherapyDrug ApprovalGene TherapyImmunotherapy

09 Dec 2025

·www.fiercepharma.com

Once public, now private, Gamida Cell scores 2nd FDA nod for stem cell therapy Omisirge

Gamida Cell has gained its second FDA green light for cell therapy Omisirge. The new nod is for treatment of patients with severe aplastic anemia. Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem-cell-based therapy to treat severe aplastic anemia (SAA).The approval, which comes more than two years after Omisirge’s original FDA nod as the first treatment to reduce the risk of infection in blood cancer patients during hematopoietic stem cell transplant, finds Gamida in a very different position. The 27-year-old Israeli company, once public, is now a subsidiary of London-based private firm Ayrmid.Gamida was cash-strapped when it got Omisirge across the regulatory finish line in April 2023. Eleven months later, its principal lender, Highbridge Capital Management, took Gamida Cell private in a restructuring deal that allowed it to stay afloat. In June 2024, Highbridge reintroduced Gamida as a wholly owned subsidiary of the U.K.'s Ayrmid.The new Omisirge approval, meanwhile, is based on a single-center study at the National Institutes of Health (NIH), which showed Gamida's cell therapy provided sustained hematopoietic recovery and transfusion independence in 86% of patients. The treatment also helped patients achieve rapid neutrophil recovery post-transplant at a median of 11 days. There were no cases of severe acute or chronic graft-versus-host disease (GVHD) in the study, Gamida's parent Ayrmid said in an early December press release. Gamida's drug further helped patients log a 92% disease-free and overall survival rate in the trial, Ayrmid added.“Patients in the study with aplastic anemia were high risk but had significantly better than expected outcomes and demonstrated remarkably fast and high rates of neutrophil engraftment,” Richard Childs, M.D., of the NIH’s National Heart, Lung, and Blood Institute, said in a release, adding that patients “achieved a rapid return to a normal life.” SAA is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient blood cells. While stem cell transplant offers a potential cure, many patients lack a matched sibling donor, Ayrmid said.“This approval is potentially transformative for patients living with SAA, given the rapid and sustained recovery of blood counts observed,” Ayrmid CEO Joe Wiley said in the release.The company added that in anticipation of the increased demand for Omisirge, it has partnered with third-party manufacturer RoslinCT. Commercial production will begin in 2027 at RoslinCT’s cell therapy manufacturing facility in Hopkinton, Massachusetts, in the U.S. Gamida's Omisirge isn’t the only product in Ayrmid’s portfolio. In November of last year, the company struck a $97 million licensing deal with BioLineRx to commercialize its cell therapy Aphexda. The treatment, which was endorsed by the FDA in 2023, is used in tandem with colony-stimulating factor (CSF) filgrastim to mobilize hematopoietic stem cells to peripheral blood for collection and autologous stem cell transplant in patients with multiple myeloma.Earlier this year, Ayrmid made an unsuccessful attempt to buy out bluebird bio for $4.50 per share. The struggling gene therapy specialist opted for Carlyle and SK Capital's competing offer at $3 per share after Ayrmid failed to obtain financing and did not deliver a binding offer after a three-week diligence period.

Cell TherapyLicense out/inDrug ApprovalClinical StudyAcquisition

24 Nov 2025

·www.fiercebiotech.com

Versant\'s Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission

It\'s a new Day(ra), and a new biotech has risen from Versant Ventures\' research labs.\n VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.The biopharma has paid $50 million upfront to enter a research pact with Toronto-based Dayra, according to a Nov. 24 release. Beyond Biogen’s cash payment, the new biotech has also locked in an equity commitment of $20 million from Versant.Together, Dayra and Biogen aim to discover and develop oral macrocyclic peptides for undisclosed targets in immunological diseases, according to a separate release. Macrocyclic peptides—such as the antifungal Rezzayo or multiple myeloma treatment Aphexda—are known for their target specificity and increased potency and durability. However, efforts to systematically develop macrocycles have run into challenges tied to pharmacokinetics, cell permeability and oral bioavailability.Dayra believes oral versions of the drug class could possibly boost specificity even more and access target protein binding sites that traditional small molecule drugs struggle to reach. And the biotech isn’t the only one who thinks that.Earlier this year, argenx penned a pact worth $1.5 billion in biobucks with Californian biotech Unnatural Products in hopes of generating orally available macrocyclic peptide action against a range of undisclosed “undruggable” targets.Big Pharma Merck & Co. has also hailed macrocyclic peptides as the “next wave of drug discovery,” supporting Unnatural Products and even inking its own deal with the biotech in 2024. In the newly announced partnership, Biogen will have the chance to acquire the development candidates for a potential additional payment per program. Preclinical and clinical development milestone payments are also on the table for each program.“With this collaboration, we are adding another potential best-in-class approach to our early-stage portfolio to target multiple high-value immunological conditions,” Jane Grogan, Ph.D., Biogen’s executive vice president and research head, said in the release.“Building on multiple technical advances in the field, we believe Dayra Therapeutics’ state-of-the-art macrocycle discovery platform could help realize the full potential of macrocycle-based treatments,” she added.In recent days, the company—known for its neuroscience efforts—has been doubling down on its immunology roots, Uptal Patel, M.D., head of Biogen’s West Coast hub, told Fierce Biotech. As for Dayra, the company emerges from Versant’s Frontier Discovery Engine—the firm’s state-of-the-art research labs—in Toronto and Montreal. The biotech says it is taking aim at creating oral macrocyclic peptides across a range of conditions.Dayra touts a macrocycle discovery platform that it combines with computational design and modeling to create novel drugs. “The field of macrocycles is at a new inflection point and is starting to deliver meaningful medicines,” Rami Hannoush, Ph.D., Dayra’s acting CEO and Versant venture partner, said in the release. “Dayra has brought together insights and enablement from Versant’s Frontier Discovery Engine, exceptional leadership with deep macrocycle drug development expertise, and this foundational collaboration with Biogen, putting the company in a very strong position.”Hannoush is joined by Roger Palframan, Ph.D., who serves as the biotech’s chief scientific officer. Before Dayra, Palframan spent more than 18 years at Belgium-based UCB.Dayra is one of the several biotechs coming from Versant this year, following autoimmune disease startup Granite Bio and obesity-focused Helicore Biopharma. Since Versant’s founding in 1999, more than 100 of the VC’s companies have been acquired or successfully debuted on the public market, according to the firm.

PDC

100 Deals associated with Motixafortide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14939

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	United States	Ayrmid Pharma Limited	08 Sep 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Ductal Carcinoma	Phase 2	China	BioLineRx Ltd.	28 Jun 2022
Pancreatic Ductal Carcinoma	Phase 2	China	Genfleet Therapeutics (Shanghai), Inc.	28 Jun 2022
Adult Lymphoblastic Lymphoma	Phase 2	United States	Washington University School of Medicine	02 Dec 2016
Precursor T-cell lymphoblastic lymphoma	Phase 2	United States	Washington University School of Medicine	02 Dec 2016
Refractory T Acute Lymphoblastic Leukemia	Phase 2	United States	Washington University School of Medicine	02 Dec 2016
Metastatic Pancreatic Cancer	Phase 2	United States	BioLineRx Ltd.	01 Sep 2016
Metastatic Pancreatic Cancer	Phase 2	Israel	BioLineRx Ltd.	01 Sep 2016
Metastatic Pancreatic Cancer	Phase 2	Spain	BioLineRx Ltd.	01 Sep 2016
Pancreatic adenocarcinoma metastatic	Phase 2	United States	BioLineRx Ltd.	01 Sep 2016
Pancreatic adenocarcinoma metastatic	Phase 2	Israel	BioLineRx Ltd.	01 Sep 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	Anemia, Sickle Cell	10	Motixafortide	easlvyqoqo(encuewctuf) = The most common adverse events were induration at the injection site (92%), pruritus with rash or hives (88%), and local or generalized pain (62%, narcotics used in 41%). There were 2 instances of lip swelling and fever, but no cases of anaphylaxis. Two patients required prolonged hospitalization for pain management, one attributed to VOE. ohngxlvzjb (ucnnvincnp )	Positive	06 Dec 2025
NCT06547112 (ASH2025)	Phase 2	Multiple Myeloma	20	Motixafortide + G-CSF (standard dosing)	ymqhithnai(tqibtnovun) = Following enhanced premeds, injection site reactions (e.g. pain, erythema, edema) of any grade occurred in 40% of patients (35% Grade 1, 5% Grade 3) relative to historical rates of 95.5% with single-agent premed and 80% with combination premeds; while systemic reactions (e.g. pruritis, flushing, rash) occurred in 40% of patients (30% Grade 1, 10% Grade 2) relative to historical rates of 90.9% with single-agent premed and 20% with combination premeds. khxtagrkhh (gxbrfxtffd )	Positive	06 Dec 2025
				Motixafortide + G-CSF (early dosing)
NCT04543071 (CheMo4METPANC, ASCO2025) Manual	Phase 2	Pancreatic adenocarcinoma metastatic	11	Motixafortide + cemiplimab + gemcitabine + nab-paclitaxel	frkduklxqi(jmfvgfrzhc) = zqonhusinh vxssaxepad (gllnsmqcia ) View more	Positive	30 May 2025
NCT02502968 (BLAST trial, EHA2025)	Phase 2	Acute Myeloid Leukemia Consolidation CXCR4	128	Motixafortide	zrnaakcsnd(hjagxnqipp) = hcykbqcayn vudwanmrhe (ibkjsmhzuq ) View more	Negative	14 May 2025
				Placebo	zrnaakcsnd(hjagxnqipp) = zthdidgtym vudwanmrhe (ibkjsmhzuq )
NCT02907099 (P328, CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	20	BL-8040+Pembrolizumab	gwqjrxqmcu = fbsabnohsg uedknujxqx (eoldracnog, aumcggdbbl - mgwvnzjmjz) View more	-	19 Feb 2025
NCT03154827 (CTgov)	Phase 1/2	Acute Myeloid Leukemia	1	BL-8040+Atezolizumab	klvhnmazoi(cuktbznusx) = azlffziqsg uchbsujzbe (dcjazyejsq, urldturpsm - tsygorlcfh) View more	-	05 Sep 2024
NCT02826486 (COMBAT/KEYNOTE-202 \| COMBAT, CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	80	BL-8040+Pembrolizumab (Cohort 1: BL-8040 + Pembrolizumab)	rpfrqlcefh = ituavjvskl bmgmdnzhlq (aaihohgpkc, ddiwjmpxmo - njxnxsnmoi) View more	-	28 Aug 2024
				BL-8040+Pembrolizumab (Cohort 2: BL-8040 + Pembrolizumab + Chemotherapy)	rpfrqlcefh = udxekkvkou bmgmdnzhlq (aaihohgpkc, gdswjcvzbc - kyojnfvbdx) View more
NCT05293171 (Tandem Meetings ASTCT and CIBMTR2024)	Phase 1	CD34+	-	Motixafortide 1.25mg/kg	gjmfnvaqqk(fwiamstsme) = zkkxjxygah oobrqfxzmc (erlfmlkhxn ) View more	-	01 Feb 2024
				G-CSF + Motixafortide 1.25mg/kg	gjmfnvaqqk(fwiamstsme) = kiucqgqype oobrqfxzmc (erlfmlkhxn ) View more
NCT03246529 (GENESIS trial \| GENESIS, CTgov)	Phase 3	Multiple Myeloma	180	G-CSF+BL-8040 (BL-8040 + G-CSF Part 1)	cierrainrs = dunjykbkrm bcolfbfgoa (julbqcgfcb, twenmcykmz - edfelhvobw) View more	-	07 Nov 2023
				G-CSF+BL-8040 (BL-8040 + G-CSF Part 2)	ckunwlcaje = fixsxmieno hwstixnkmk (kylhkxxhsv, eisarlcumd - mvnemajmaa) View more
NCT02763384 (CTgov)	Phase 2	Precursor T-cell lymphoblastic lymphoma \| Refractory T Acute Lymphoblastic Leukemia \| Adult Lymphoblastic Lymphoma	12	BL-8040+Nelarabine	rrmvrwdjlq = wxurvzwxie zfrnudsode (szrchxecka, rdkrgnexeq - nctduusplc) View more	-	31 Oct 2023

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Motixafortide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation